Testing of viscous anti-HIV microbicides usingLactobacillus

Publication year: 2011 Source: Journal of Microbiological Methods, Available online 24 December 2011 B.J. Moncla, K. Pryke, L.C. Rohan, H. Yang The development of topical microbicides for intravaginal use to prevent HIV infection requires that the drugs and formulated products be nontoxic to the endogenous vaginalLactobacillus. In 30 min exposure tests we found dapivirine, tenofovir and UC781 (reverse transcriptase inhibitor anti-HIV drugs) as pure drugs or formulated as film or gel products were not deleterious toLactobacillusspecies; however, PSC-RANTES (a synthetic CCR5 antagonist) killed 2 strains ofLactobacillus jensenii.

Publication year: 2011 Source: Journal of Microbiological Methods, Available online 24 December 2011 B.J. Moncla, K. Pryke, L.C. Rohan, H. Yang The development of topical microbicides for intravaginal use to prevent HIV infection requires that the drugs and formulated products be nontoxic to the endogenous vaginalLactobacillus. In 30 min exposure tests we found dapivirine, tenofovir and UC781 (reverse transcriptase inhibitor anti-HIV drugs) as pure drugs or formulated as film or gel products were not deleterious toLactobacillusspecies; however, PSC-RANTES (a synthetic CCR5 antagonist) killed 2 strains ofLactobacillus jensenii.

Continued here:
Testing of viscous anti-HIV microbicides usingLactobacillus